Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | NAMPT | P43490 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | PRKCA | P17252 | 2/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20462570 | 0.82 | OPRM1 (0.38) | POLBPRKCAHDAC6 | |
| SCHEMBL20464429 | 0.81 | ADA (0.35) | POLBPRKCAHDAC6 | |
| SCHEMBL20462571 | 0.78 | OPRM1 (0.33) | POLBPRKCAHDAC6 | |
| SCHEMBL9989965 | 0.78 | EPHX1 (0.44) | EPHX1POLBNAMPTNPC1RAB9A | |
| SCHEMBL15461403 | 0.78 | EPHX1 (0.44) | EPHX1POLBNAMPTNPC1RAB9A | |
| SCHEMBL21246176 | 0.76 | EPHX1 (0.43) | EPHX1POLBNAMPTNPC1RAB9A | |
| SCHEMBL18347931 | 0.73 | EPHX1 (0.40) | EPHX1POLBNAMPTNPC1RAB9A | |
| SCHEMBL19652196 | 0.73 | OPRM1 (0.39) | — | |
| SCHEMBL28537036 | 0.70 | HCRTR2 (0.37) | EPHX1POLBNAMPT | |
| SCHEMBL20462573 | 0.69 | POLB (0.33) | POLBNAMPTPRKCAHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10487068-B2 | Pyridazine derivatives as RORc modulators | GENENTECH, INC. (US) | 2019-11-26 | — | — | US | disclosed |
| US-20180222882-A1 | PYRIDAZINE DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2018-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10487068-B2 | Pyridazine derivatives as RORc modulators | RORC, RORB, RORA | EPHX1 1296/4885POLB 3888/4885NAMPT 1411/4885 |
| US-20180222882-A1 | PYRIDAZINE DERIVATIVES AS RORc MODULATORS | RORC, RORB, RORA | EPHX1 1296/4885POLB 3888/4885NAMPT 1411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.